Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.

Zacks Investment Research • Aug 4, 2026

Krystal Biotech Q2 Earnings Call Highlights

Krystal Biotech NASDAQ: KRYS reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded treatment access for patients with dystrophic epidermolysis bullosa, or DEB, in the United States and overseas.

MarketBeat • Aug 3, 2026

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 3, 2026

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance sheet, ending the quarter with $1.1 billion in cash and investments PITTSBURGH, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company” or “Krystal”) (NASDAQ: KRYS) today reported financial results for the second quarter ended June 30, 2026 and provided a business update. “Our second quarter reflects the strength of the Krystal model: a global commercial product that continues to perform, a strong balance sheet, and a pipeline now moving toward multiple registrational readouts,” said Krish S.

GlobeNewsWire • Aug 3, 2026

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.79 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $1.29 per share a year ago.

Zacks Investment Research • Aug 3, 2026

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

Investors Business Daily • Aug 3, 2026

Krystal Biotech: Profitable, Self-Funding, And Loaded With Optionality

Krystal Biotech remains a Buy as VYJUVEK drives profitability and its HSV-1 platform underpins a robust pipeline. Q1 results highlight operating leverage: $116.4M VYJUVEK revenue, $56M net income, and self-funded R&D with a $1B cash position. Upcoming catalysts include registrational data for KB803 and KB801, with KB801 positioned as a potential blockbuster in rare ophthalmology.

Seeking Alpha • Jul 29, 2026

Krystal Biotech: International Expansion And A Vibrant Pipeline

Krystal Biotech (KRYS) earns a STRONG BUY rating, driven by its fortress-like balance sheet, exceptional margins, and rapid Vyjuvek commercial success. KRYS's international Vyjuvek launches in Europe and Japan are accelerating topline growth, with further expansion into Italy, Spain, and the UK expected to boost revenues. KRYS's pipeline, leveraging its proprietary HSV-1 platform, spans respiratory, ophthalmology, oncology, and aesthetics, reducing future reliance on Vyjuvek.

Seeking Alpha • Jul 29, 2026

Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Jul 27, 2026

These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead

Krystal Biotech is posting strong sales thanks to a breakthrough in an underserved therapeutic area. Exelixis has carved out a niche in the cancer-drug market, which much larger companies typically dominate.

The Motley Fool • Jul 24, 2026